$26M Capped ASX Stock Generating Millions in Revenue: US and Chinese Markets are Next

Jun 14, 2016

With a total global market of $90 billion, successful hair loss products can generate hundreds of millions of dollars in revenue. However the current market leaders may soon be under pressure from one particular ASX listed life sciences company.

read article

Multi-Billion Alzheimer’s Drug Development Boom Underway: ACW Well Positioned in Phase II Trials

Jun 08, 2016

Prominent US financial institution JP Morgan recently released a rather bullish report on Alzheimer’s disease – a sector they think represents one of the most attractive up and coming categories in biotech.

read article

FDA Approval for MXC: Sales Doors Open in US, Euro and Canadian Markets

May 31, 2016

When the US Food and Drug Administration (FDA) gives companies its seal of approval, it usually signals the start of a fully endorsed, regulatory-approved push into large commercial markets. No matter what industry a company operates in, FDA product approval is a big milestone.

read article

DXB to Hit Major Milestone: Early Phase II Results Due in Coming Weeks

May 25, 2016

Within the next quarter, $12M capped Dimerix (ASX:DXB) is due to publish early results from Phase II clinical trials of its flagship drug therapy DMX-200, a combination therapy designed to alleviate the suffering of people afflicted with Chronic Kidney Disease (CKD).

read article

Medical Cannabis Player MXC Hits First Retail Sales in US$460BN Cosmetics Market

May 04, 2016

We’ve been highlighting the changing landscape in the medical cannabis industry for quite a while. Forgotten for decades, cannabis is coming back as a soft medicine as governments the world over reconsider draconian drug enforcement policy that in hindsight, was throwing the baby out with the bathwater.

read article

Ex Pfizer VP to Repeat Market Topping Drug Development with this ASX Stock?

Apr 20, 2016

As humans continue to live longer, certain diseases start to become more apparent, causing widespread concern for the elderly and their families. One of them is Alzheimer’s disease (AD) – a horrific disease that starts off with short-term memory loss and gradually progresses to severe memory failure including forgetting your own children and family.

read article

MMJ Set to Boost Medical Cannabis Production Capacity by 1000%?

Apr 01, 2016

The market for medical cannabis is gradually moving out of the wilderness and onto government radars. The once forgotten medicine is currently being re-evaluated and reclassified in the US, Australia and Europe as its positive effect on a range of ailments is finally being rediscovered and decriminalised by governments across the globe.

read article

Private Equity Biotech Deal Maker in ASX Offering

Mar 15, 2016

Kidneys are the unsung heroes of our bodies. You may not think about it often, but your healthy kidney keeps your blood pressure regular, filters waste and toxins (i.e. adds water and creates urine), and cleans your blood.

read article

Green Light for Medical Cannabis in Australia: MMJ has First Mover Advantage

Mar 04, 2016

If you haven’t caught the news over the course of the previous week, Australia has moved to make the growth of medical cannabis legal and the medical cannabis commercial industry a reality.

read article

First Revenues from MXC’s Cannabidiol Cosmetics Line Imminent

Feb 23, 2016

The growth of the medical cannabis industry is gaining momentum. Even doctors are talking more about its use in the treatment of ailments such as skin diseases and in the reduction of pain.

read article

MMJ’s Medical Cannabis Pill Performs Better than A$1.2BN Capped Competitor

Feb 11, 2016

MMJ Phytotech (ASX:MMJ) has put themselves at the front of the queue to start commercialising medical cannabis as and when government officials give the green light.

read article

Is a Cannabis Cultivation License Now Just Days Away for MMJ?

Jan 21, 2016

Last week a crucial piece of news hit emerging pharmaceutical company MMJ Phytotech (ASX:MMJ). In what is known as a ‘Pre-License Inspection’, Federal health inspectors at Health Canada will examine MMJ’s Canadian medicinal cannabis growing facilities.

read article

Cannabis Gets Cosmetic Makeover: ASX Shell with Imminent Acquisition into $270BN Industry

Nov 11, 2015

The use of cannabis is moving above ground as savvy businesses now look at the commercial benefits of this once infamous plant.

read article

Medical Cannabis First Mover: MMJ to Accelerate Australian Roll Out

Oct 28, 2015

The long term game that emerging medical cannabis company MMJ PhytoTech (ASX:MMJ) is playing is gradually paying off.

read article

Game Changer for MMJ: First CBD Pill Sales Confirmed

Sep 01, 2015

MMJ PhytoTech (ASX:MMJ) is about to play a whole new ballgame. It’s just announced first sales of its cannabidoil (CBD) pill, and with it, all important first revenue.

read article

ASX Company to Disrupt $916BN Big Pharma Industry?

Jul 20, 2015

MMJ Phytotech Limited (ASX:MMJ) is a pharmaceutical company that’s pioneering the development of therapeutic compounds from the cannabis plant for international markets.

read article
Are you a sophisticated investor?
Find out more
Please note: Raisebook is a related entity of S3 Consortium Pty Ltd as defined in Section 9 of the Corporations Act 2001.